Simcere Zaiming licenses CD79a×CD19×CD3 trispecific SIM0660 to Roche
Illustration (decorative, not data).Summary
SIM0660 is a trispecific T-cell engager: one arm binds CD3 to recruit T cells, while the other two simultaneously bind the B-cell antigens CD79a and CD19. The design aims for potent B-cell depletion while keeping cytokine release low; dual-antigen coverage is also intended to serve patients previously treated with CD20 or CD19 therapies who may have antigen loss. Roche obtains exclusive global rights. The asset is still preclinical or early stage with no specific indication disclosed; the company describes it as aimed at both B-cell malignancies and autoimmune disease. It is another molecular design, after CD19×CD3, in the “T-cell engagers that deplete B cells to treat autoimmunity” theme.
Deal terms, as disclosed
$75M upfront + development, regulatory and commercial milestones (up to $1.53B total) + tiered double-digit royalties.
Summary of public disclosures, not investment advice. Amounts are as announced; milestone payments are contingent and may never be paid.
Related same deal type
- Novartis takes global rights to Abogen's in vivo mRNA T-cell engager ABO2203Oct 2026
- Haisco immunology asset goes into ARCH-founded NewCo SentiveraAug 2026
- J&J locks up Sail Biomedicines' in vivo CAR-T with an equity stake and an acquisition optionJul 2026
- GemPharmatech and Humlab partner on global distribution of humanized mouse modelsJul 2026
Asset owners and investors: write to bd@inlightbio.com. Newsletter and report questions: contact@inlightbio.com.